Proven Results - Postmenopausal

KISQALI® (ribociclib) + HORMONE THERAPY OR FULVESTRANT

MBC WASN’T IN MY PLANS. BUT I PLAN ON TAKING IT HEAD ON.

Live longer
without disease progression

KISQALI® (ribociclib) tablets along with hormone therapy (eg, letrozole or anastrozole) or fulvestrant is a treatment option for postmenopausal women with HR+, HER2- metastatic breast cancer. Here are some proven results that show how KISQALI may help.

Proven Results With KISQALI

KISQALI® + fulvestrant Progression-free SurvivalMedian time womenlivedwithoutdiseaseprogressionfrom the startoftreatment0 months15months30months12.8fulvestrantaloneKISQALI+fulvestrantTrials are still ongoingto see if patients live longer with treatment20.520.5 months of progression-free survival

KISQALI + fulvestrant

KISQALI is used along with the medicine fulvestrant in postmenopausal women who are either newly diagnosed with HR+, HER2- metastatic breast cancer, or who have already received hormone therapy.

Results with KISQALI® + fulvestrant41%29%41% of women taking KISQALI + fulvestrant had tumors that shrank or disappeared vs 29% of women taking fulvestrant alone.*

*39% of women taking KISQALI + fulvestrant saw their tumors shrink in size vs 29% of those taking fulvestrant alone. And 2% of women taking KISQALI + fulvestrant had their tumors completely disappear vs 0% of those taking fulvestrant alone.

Proven to shrink tumors

In a clinical trial, 726 patients were treated with either KISQALI + fulvestrant or fulvestrant alone. KISQALI + fulvestrant worked together to shrink tumors in women who had measurable tumors.

KISQALI® + letrozole Progression-free SurvivalMedian time womenlivedwithoutdiseaseprogressionfrom the startoftreatment0 months15 months30 months25.316.0letrozolealoneKISQALI+letrozoleAs measured during a trial follow-upTrials are still ongoingto see if patients live longer with treatment2+ years of progression-free survival

KISQALI + letrozole

KISQALI works in combination with a hormone therapy to delay the progression of metastatic breast cancer in postmenopausal women. In a clinical trial of 668 women, KISQALI + letrozole reduced the risk of disease progression by 44% vs letrozole alone. At the time of this analysis, more than half of women taking KISQALI + letrozole remained alive and progression free.

Results with KISQALI® + letrozoleMORETHANHALF53% of women taking KISQALI + letrozole had tumors that shrank or disappeared vs 37% of women takingletrozole alone. 3 out of 4 Women saw tumor shrinkage at the first trial check-in (observed 8 weeks after starting treatment)3 OUT OF 4 WOMENsaw tumor shrinkageat the first trial check-in (observed 8 weeks after starting treatment).This check-in was not designed to measure tumor size reduction. Based on the design of the trial, this result may not have been caused by the treatment.

†50% of women taking KISQALI + letrozole saw their tumors shrink in size vs 35% of those taking letrozole alone. And 3% of women taking KISQALI + letrozole had their tumors completely disappear vs 2% of those taking letrozole alone.

Proven to shrink tumors

KISQALI and letrozole worked together to shrink tumors in women who had measurable tumors.

The Face of Metastatic Breast Cancer

Watch the KISQALI® (ribociclib) video to meet three women who are representing the experience of living with HR+, HER2- metastatic breast cancer. Listen as they discuss the importance of advocating for yourself, and learn about proven treatment results seen with KISQALI.

The Face of mBC
01:30